All samples·Sample analysis
Get your own pass — $199
granted.bioAll samples
Analysis

radioligand therapy for prostate cancer

Overview
  • Dashboard
Analysis
  • What Surprised Us
  • Field Maturity
  • Funding Landscape
  • Competitive Topology
  • White Space
  • Market Context
Data
  • Projects115
  • Clinical Trials500
  • Patents29
  • Publications646
  • Organizations52
  • Researchers125
Reference
  • Methodology
Back
radioligand therapy for prostate cancerOrganizationsUNIVERSITY OF IOWA

UNIVERSITY OF IOWA

Projects attributed to UNIVERSITY OF IOWA within this analysis sample.

In This Analysis
Projects
2
NIH Funding
$571K
Projects(2)
ProjectPICategoryFunding
Project 2: Targeting CXCR4 and Redox Metabolism for Targeted Alpha Therapy of Pulmonary Neuroendocrine Tumors and Carcinomas
1P50CA302572-01
SPITZ, DOUGLAS ROBERTInfrastructure$404K
Alpha-Particle Emitter Peptide Receptor Targeted Radionuclide Therapy for Neuroendocrine Tumors
5R01CA243014-06
MENDA, YUSUFTherapeutics$167K
See UNIVERSITY OF IOWA’s full platform profile
Cross-source view across the entire granted.bio dataset — projects, trials, patents, and publications spanning every topic, not just this analysis.